Long-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis (Open-Label Extension Study)

Amy S. Paller, Northwestern University The Feinberg School of Medicine, Wilmette, IL, United States; Michele Ramien, Alberta Children's Hospital, Calgary, AB, Canada; Michael J. Cork, Sheffield Dermatology Research, University of Sheffield, Sheffield Children’s Hospital, Sheffield, England, United Kingdom; Eric L. Simpson, Oregon, Po, OR, United States; LARA Wine LEE, Medical University of South Carolina, Charleston, SC, United States; Lawrence F. Eichenfield, University of California, San Diego, CA, United States; Anna Coleman, Regeneron Pharmaceuticals Inc., Dublin, Dublin, Ireland; Guy Gherardi, Sanofi, Reading, England, United Kingdom; Zhen Chen, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States; Annie Zhang, Sanofi, Cambridge, MA, United States; Sonya L. Cyr, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States